Surrozen banks $50M round to fuel its drive to the clinic with regenerative med platform
Two years after gaining a $33 million launch round for its regenerative medicine platform tech, the Bay Area biotech Surrozen has gone back to the well to raise $50 million to fuel its drive into the clinic.
The key figure in this startup is Christopher Garcia, a Stanford investigator who’s been drawn into the world of Wnt. While much of his labor has centered on cancer research, he’s also spent time developing Wnt surrogates that can play the same role as natural proteins in forming tissue and spurring repair, but hopefully with better drug-like properties that will make them simpler to manufacture and test in humans.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
